Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...

The Supreme Court heard a challenge to a Colorado law banning "conversion therapy" for minors that was brought by a licensed ...

In the third century BCE, Apollonius of Perga asked how many circles one could draw that would touch three given circles at exactly one point each. It would take 1,800 years to prove the answer: eight ...

The US Supreme Court heard a case Tuesday that will determine whether a Colorado law that prohibits licensed mental health ...

When a user opens Outlook, it displays your primary inbox and content pane, but what if you want Outlook to open the mail module displaying another folder instead of the default inbox folder. Outlook ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

FAYETTEVILLE, Ark. – Arkansas has made a change in the leadership of the football program with the dismissal of Head Coach Sam Pittman by Vice Chancellor and Director of Athletics Hunter Yurachek.

BOSTON - The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Vertex Pharmaceuticals’ (NASDAQ:VRTX) povetacicept for the treatment of IgA nephropathy, a serious kidney ...

The changes to the citizenship process signal a shift toward stricter vetting. In a press release, USCIS said the changes were part of "an ongoing effort to restore integrity to the naturalization ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...